435 related articles for article (PubMed ID: 33906820)
1. Tumor resident regulatory T cells.
Glasner A; Plitas G
Semin Immunol; 2021 Feb; 52():101476. PubMed ID: 33906820
[TBL] [Abstract][Full Text] [Related]
2. Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting.
Aristin Revilla S; Kranenburg O; Coffer PJ
Front Immunol; 2022; 13():903564. PubMed ID: 35874729
[TBL] [Abstract][Full Text] [Related]
3. FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity.
Whiteside TL
Expert Opin Ther Targets; 2018 Apr; 22(4):353-363. PubMed ID: 29532697
[TBL] [Abstract][Full Text] [Related]
4. Role of CD4
Hariyanto AD; Permata TBM; Gondhowiardjo SA
Immunol Med; 2022 Jun; 45(2):94-107. PubMed ID: 34495808
[TBL] [Abstract][Full Text] [Related]
5. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
6. Targeting Treg cells in cancer immunotherapy.
Tanaka A; Sakaguchi S
Eur J Immunol; 2019 Aug; 49(8):1140-1146. PubMed ID: 31257581
[TBL] [Abstract][Full Text] [Related]
7. Reprogramming of regulatory T cells in inflammatory tumor microenvironment: can it become immunotherapy turning point?
Liu J; Zhang B; Zhang G; Shang D
Front Immunol; 2024; 15():1345838. PubMed ID: 38449875
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
Kumar P; Saini S; Prabhakar BS
Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
[TBL] [Abstract][Full Text] [Related]
9. Treg Fragility: A Prerequisite for Effective Antitumor Immunity?
Overacre-Delgoffe AE; Vignali DAA
Cancer Immunol Res; 2018 Aug; 6(8):882-887. PubMed ID: 30068755
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity.
Yano H; Andrews LP; Workman CJ; Vignali DAA
Immunology; 2019 Jul; 157(3):232-247. PubMed ID: 31087644
[TBL] [Abstract][Full Text] [Related]
11. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
13. Immunometabolism of regulatory T cells in cancer.
Galgani M; Bruzzaniti S; La Rocca C; Micillo T; de Candia P; Bifulco M; Matarese G
Mol Aspects Med; 2021 Feb; 77():100936. PubMed ID: 33250195
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies.
Nishikawa H; Koyama S
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330764
[TBL] [Abstract][Full Text] [Related]
15. Novel anti-GARP antibody DS-1055a augments anti-tumor immunity by depleting highly suppressive GARP+ regulatory T cells.
Satoh K; Kobayashi Y; Fujimaki K; Hayashi S; Ishida S; Sugiyama D; Sato T; Lim K; Miyamoto M; Kozuma S; Kadokura M; Wakita K; Hata M; Hirahara K; Amano M; Watanabe I; Okamoto A; Tuettenberg A; Jonuleit H; Tanemura A; Maruyama S; Agatsuma T; Wada T; Nishikawa H
Int Immunol; 2021 Jul; 33(8):435-446. PubMed ID: 34235533
[TBL] [Abstract][Full Text] [Related]
16. Targeting regulatory T cells in tumors.
Liu C; Workman CJ; Vignali DA
FEBS J; 2016 Jul; 283(14):2731-48. PubMed ID: 26787424
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic targeting of regulatory T cells in cancer.
Shan F; Somasundaram A; Bruno TC; Workman CJ; Vignali DAA
Trends Cancer; 2022 Nov; 8(11):944-961. PubMed ID: 35853825
[TBL] [Abstract][Full Text] [Related]
18. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
Ohue Y; Nishikawa H
Cancer Sci; 2019 Jul; 110(7):2080-2089. PubMed ID: 31102428
[TBL] [Abstract][Full Text] [Related]
19. FoxP3
Saleh R; Elkord E
Cancer Lett; 2020 Oct; 490():174-185. PubMed ID: 32721551
[TBL] [Abstract][Full Text] [Related]
20. Regulatory T-cell development in the tumor microenvironment.
Itahashi K; Irie T; Nishikawa H
Eur J Immunol; 2022 Aug; 52(8):1216-1227. PubMed ID: 35879813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
